Table 4.
Log-rank univariate regression results for OS. *p-value < 0.05.
| Baseline parameters | n | HR | lower | upper | p-value |
|---|---|---|---|---|---|
| Age (yr) | |||||
| <70(ref) | 27 | ||||
| >70 | 22 | 1.06 | 0.60 | 1.87 | 0.9 |
| Gender | |||||
| Male (ref) | 37 | ||||
| Female | 12 | 1.39 | 0.72 | 2.71 | 0.3 |
| GTV (cm3) | |||||
| <113 (ref) | 22 | ||||
| >113 | 27 | 1.82 | 1.01 | 3.30 | 0.04* |
| Histology | |||||
| LUAD (ref) | 26 | ||||
| LUSQ and LCC | 23 | 1.48 | 0.82 | 2.66 | 0.2 |
| Stage | |||||
| 3 (ref) | 14 | ||||
| 4 | 32 | 1.02 | 0.54 | 1.94 | 0.9 |
| CRP/Albumin | |||||
| <0.12 (ref) | 12 | ||||
| >0.12 | 32 | 2.68 | 1.30 | 5.53 | 0.005* |
| Monocyte/Lymphocyte | |||||
| <0.28 (ref) | 17 | ||||
| >0.28 | 32 | 1.75 | 0.95 | 3.20 | 0.07 |
| Neutrophil/Lymphocyte | |||||
| <4 (ref) | 24 | ||||
| >4 | 25 | 1.75 | 0.98 | 3.14 | 0.06 |
| ECOG PS = 2 | |||||
| No (ref) | 35 | ||||
| Yes | 14 | 0.90 | 0.47 | 1.73 | 0.7 |
| Neutrophilia | |||||
| No (ref) | 26 | ||||
| Yes | 23 | 1.21 | 0.68 | 2.15 | 0.4 |
| Leukocytosis | |||||
| No (ref) | 26 | ||||
| Yes | 23 | 1.18 | 0.66 | 2.08 | 0.6 |
| Therapeutic parameters | |||||
| Corticosteroid use | |||||
| No (ref) | 31 | ||||
| Yes | 16 | 2.45 | 1.28 | 4.70 | 0.005* |
| Lymphopenia ≥ G3 | |||||
| No (ref) | 39 | ||||
| Yes | 10 | 1.27 | 0.63 | 2.58 | 0.5 |
| Mean thoracic dose | |||||
| <5Gy (ref) | 29 | ||||
| >5Gy | 20 | 2.12 | 1.16 | 3.88 | 0.01* |
Abbreviations: HR: Hazard ratio; GTV: gross tumor volume; LUAD: lung adenocarcinoma; LUSQ: lung squamous carcinoma; LCC: large cell carcinoma; CRP: C-reactive protein; ECOG PS: eastern cooperative oncology group performance status.